201 completed, 103 recruiting, 89 unknown, 63 terminated. 568 Phase 2, 134 Phase 1, 16 Phase 3.
Follow Uterine Cervical Neoplasms: new trials by email Literature Review of Uterine Cervical Neoplasms trials Research Report on Uterine Cervical Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Curcumin for HPV Related Cervical Disease Curcumin C3 Complex, Placebo - Neoplasm Cervix | Phase 2 | Not yet recruiting | Lisa Flowers | 200 | 2027-04-01 | 2026-05-08 |
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Telaglenastat, Radiation treatment, Cisplatin - Advanced Cervical Carcinoma, Cervical Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 42 | 2026-12-31 | 2026-09-03 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Adaptive Radiotherapy for Safe Hypofractionation Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy - Cancer, Endometrial Cancer | Phase 2 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 264 | 2026-11-01 | 2026-10-29 |
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer Relacorilant, Nab-paclitaxel - Recurrent or Metastatic Cervical Cancer | Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 63 | 2026-10-01 | 2026-08-13 |
| Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Mark Bernard | 35 | 2026-09-09 | 2026-10-14 |
| Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya 5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-09-01 | 2026-08-27 |
| Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial Adebrelimab - Cervical Neoplasms | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 35 | 2026-08-01 | 2026-07-28 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin - Uterine Cervical Neoplasms, Locally Advanced | Phase 2 | Recruiting | Sun Yat-sen University | 103 | 2026-07-01 | 2026-06-12 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer Camrelizumab, Famitinib Malate, Chemotherapy - Cervical Cancer | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | 54 | 2026-06-30 | 2026-06-04 |
| An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy Zanidatamab - Neoplasms, Solid Tumors | Phase 2 | Not yet recruiting | Haihua Yuan | 10 | 2026-06-15 | 2026-06-08 |
| QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy - Cervical Cancer, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2026-06-15 | 2026-06-01 |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer Becotatug Vedotin in combination with Zimberelimab - Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2026-06-11 | 2026-06-16 |
| Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial Neoadjuvant Therapy Plus Surgery, Concurrent Chemoradiotherapy - Cervical Cancer | Phase 2 | Not yet recruiting | Obstetrics & Gynecology Hospital of Fudan University | 134 | 2026-06-06 | 2026-06-16 |
| A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. GV20-0251, anti-PD-1 monoclonal antibodies - Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms | Phase 2 | Not yet recruiting | GV20 Therapeutics | 227 | 2026-06-02 | 2026-06-08 |
| Engineered Immune Effectors Against Cervical Cancer CC-EIEs - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| Intervention of CAR-T Against Cervical Cancer Cervical cancer-specific CAR-T cells - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
Showing 20 of 568. Sign in to see all of them.
Ovarian Neoplasms (90) · Endometrial Neoplasms (89) · Carcinoma, Non-Small-Cell Lung (61) · Breast Neoplasms (46) · Squamous Cell Carcinoma of Head and Neck (44) · Esophageal Neoplasms (43) · Stomach Neoplasms (41) · Melanoma (39) · Vulvar Neoplasms (36) · Colorectal Neoplasms (34) · Neoplasms (34) · Pancreatic Neoplasms (34) · Vaginal Neoplasms (33) · Head and Neck Neoplasms (32)
Female Urogenital Diseases (568) · Female Urogenital Diseases and Pregnancy Complications (568) · Genital Diseases (568) · Urogenital Diseases (568) · Genital Diseases, Female (567) · Uterine Cervical Diseases (567) · Uterine Diseases (567) · Urogenital Neoplasms (566) · Neoplasms by Site (564) · Genital Neoplasms, Female (563) · Uterine Neoplasms (544) · Neoplasms (534) · Neoplasms by Histologic Type (121) · Endocrine Gland Neoplasms (110) · Endocrine System Diseases (110)
Cisplatin (87) · Paclitaxel (41) · pembrolizumab (41) · Radiotherapy (38) · Carboplatin (37) · Bevacizumab (30) · Brachytherapy (23) · Nivolumab (17) · Docetaxel (13) · atezolizumab (13) · Drug Therapy (12) · Gemcitabine (12) · Topotecan (12) · Cyclophosphamide (11) · camrelizumab (11)
National Cancer Institute (NCI) (36) · Gynecologic Oncology Group (24) · Peking Union Medical College Hospital (10) · Lei Li (8) · M.D. Anderson Cancer Center (8) · Merck Sharp & Dohme LLC (8) · Sun Yat-sen University (7) · University Health Network, Toronto (7) · Tianjin Medical University Cancer Institute and Hospital (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Dana-Farber Cancer Institute (5) · Fujian Cancer Hospital (5) · Washington University School of Medicine (5) · Women's Hospital School Of Medicine Zhejiang University (5) · Agenus Inc. (4)
United States (237) · China (159) · Canada (40) · South Korea (38) · France (34) · Spain (34) · United Kingdom (32) · Belgium (26) · Italy (24) · Australia (23) · Taiwan (21) · Germany (20) · Japan (18) · Brazil (17) · Netherlands (16)
Lei Li, M.D. (8) · Ding Ma (4) · Steven A Rosenberg, M.D. (4) · Fuquan Zhang, M.D. (3) · Michael Milosevic, MD (3) · Anthony Fyles, MD (2) · Carol Aghajanian, MD (2) · Charalampos Floudas, M.D. (2) · Charles Kunos (2) · Christian S Hinrichs, MD (2) · David S. Miller, MD (2)
PMID 37496366, PMID 41044356, PMID 21907959, PMID 25207403, PMID 27319286, PMID 41276263, PMID 11224527, PMID 11230468, PMID 11398890, PMID 11595691, PMID 11886723, PMID 12713990, PMID 12821360, PMID 14615449, PMID 14766258, PMID 14984966, PMID 15047228, PMID 15240681, PMID 15310778, PMID 15589587, PMID 15712779, PMID 15863167, PMID 15863172, PMID 16110319, PMID 16174242, PMID 16271750, PMID 16382236, PMID 16445649, PMID 16473126, PMID 16478630, PMID 16585222, PMID 16597660, PMID 16618953, PMID 16889823, PMID 17049588, PMID 17084549, PMID 17330838, PMID 17398031, PMID 17482376, PMID 17586030, PMID 17655918, PMID 17664498, PMID 17910981, PMID 18252805, PMID 18299147, PMID 18385498, PMID 18407790, PMID 18408401, PMID 18408402, PMID 18433504
U10CA027469 (12), 2023 (11), U10CA180868 (5), 2016 (4), 2018 (4), 2019 (4), 2009 (3), 2017 (3), 2014 (2), 2015 (2), U10CA180821 (2), UM1CA121947 (2), 2005 (1), 2008 (1), D43TW009759 (1)